Navigation Links
Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
Date:3/2/2011

EMERYVILLE, Calif., March 2, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Cowen and Company 31st Annual Health Care Conference on Wednesday, March 9, 2011 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).  

Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software.  For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through March 23, 2011.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
2. Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.
3. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
4. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
5. Pacira Pharmaceuticals EXPARELâ„¢ Data to be Featured at 2011 ASCPT 112th Annual Meeting
6. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
7. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
8. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
9. Access Pharmaceuticals to Host Update Conference Call for Investors
10. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
11. Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results Conference Call on March 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... 15, 2011 Amgen (NASDAQ: AMGN ... District Court in Pennsylvania has entered final judgment ... Ltd. and Teva Pharmaceuticals USA prohibiting them from ... colony-stimulating factor) and methods for its use. Today,s ...
... key component of health care reform involves the improvement ... particularly for patients admitted to a hospital. To help ... Center for Health Quality and Innovation, which provides financial ... system. The center has now awarded nine ...
Cached Medicine Technology:Amgen Resolves G-CSF Patent Litigation With Teva 2UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 2UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 3UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 4UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 5
(Date:4/23/2014)... program could help doctors predict which patients might suffer ... , The program, which assesses brain scans using pattern ... and passport control, has been developed by researchers at ... by the Wellcome Trust, which used the software are ... , Stroke affects over 15 million people each year ...
(Date:4/23/2014)... showing the potential health benefits of probiotics, antioxidants and ... supplements. And the chemical industry is getting in on ... could deter growth, so the industry is responding with ... the cover story in Chemical & Engineering News ... Chemical Society. , Melody M. Bomgardner, a senior editor ...
(Date:4/23/2014)... Five for-profit and non-profit organizations in Washington will ... of Concept grants to accelerate maturation of promising ... Life Sciences Discovery Fund (LSDF) announced today. Also ... to the Washington Biotechnology & Biomedical Association (WBBA) ... the next generation of entrepreneurs and help early-stage ...
(Date:4/23/2014)... Midlife Occupational and Leisure Time Physical Activity on Mobility ... in midlife increases the risk of mobility limitation in ... This is found in a study which followed up ... was conducted at the Gerontology Research Center in Finland ... physical labor is often repetitive, wears the body and ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... , WASHINGTON, Sept. 18 In the ... is considered a "pre-existing condition" by many health insurers, today ... police officers, war correspondents, expectant fathers, pregnant women and patients ... denied health insurance policies. , , The ...
... various routes , FRIDAY, Sept. 18 (HealthDay News) -- ... the U.S. Food and Drug Administration can be safely ... new recommendations from the American Academy of Allergy, Asthma ... responses are weakened by medical treatments (such as for ...
... , SAN FRANCISCO, Sept. 18 Quantros(TM), ... healthcare industry, today announced a partnership with HealthWatch, Inc. - a ... Care, a national, not for profit quality improvement organization - to ... , , Quantros Patient Safety Center (QPSC(TM)), the ...
... Sept. 18 happier.com is a ... designed to help people not just be happier but "do happier. ... for users to make an immediate positive impact on ... by taking 4 validated tests with instant feedback on ...
... , Active sculptor and wood carver makes quick return ... six years of dialysis finally began to take a heavy toll on 84-year-old ... his art, and he was unable to travel, which is a major source ... patriarch to an expansive family. He,s the father of four, grandfather of five ...
... SHANGHAI, Sept. 18 /PRNewswire-Asia/ -- Avery Dennison Specialty Tape,Division, ... sector,introduced two new ultra-thin adhesives and a hydrocolloid and ... (Photo: http://www.prnasia.com/sa/2009/09/18/20090918839634.html ) , ... entire spectrum of wound care and for the most,demanding ...
Cached Medicine News:Health News:Pre-Existing Health 'Conditions' - Cops, Firefighters, Expectant Dads, and Those Suffering From Allergies, Acne and Toenail Fungus Are Uninsurable According to Internal Documents 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 3Health News:Quantros and HealthWatch Announce PSO Partnership 2Health News:Quantros and HealthWatch Announce PSO Partnership 3Health News:https://happier.com/form.htmhappier.com Launches a Personal Trainer for Your Happiness 2Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 2Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 3Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 4Health News:Avery Dennison Introduces Advanced New Medical Dressing Technology at MEDTEC China 2009 2Health News:Avery Dennison Introduces Advanced New Medical Dressing Technology at MEDTEC China 2009 3
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
... new Nanopipetting System Genesis NPS based on ... allows you to miniaturize your assays for ... picking and direct dilutions., Furthermore it ... applications including gene expression analysis, gene mapping, ...
Medicine Products: